TWI538912B - Trpv4拮抗劑 - Google Patents

Trpv4拮抗劑 Download PDF

Info

Publication number
TWI538912B
TWI538912B TW101121449A TW101121449A TWI538912B TW I538912 B TWI538912 B TW I538912B TW 101121449 A TW101121449 A TW 101121449A TW 101121449 A TW101121449 A TW 101121449A TW I538912 B TWI538912 B TW I538912B
Authority
TW
Taiwan
Prior art keywords
methyl
oxo
carbonitrile
azirocyclo
dec
Prior art date
Application number
TW101121449A
Other languages
English (en)
Chinese (zh)
Other versions
TW201313705A (zh
Inventor
卡爾 布魯克
張玫
希拉蕊 亞當
克斯塔 古德曼
瑪里斯 哈門
馬克 席菲格
創 宏
傑克琳 帕德森
派翠克 史得利
葉國森
Original Assignee
葛蘭素史密斯克萊有限責任公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47558389&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TWI538912(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 葛蘭素史密斯克萊有限責任公司 filed Critical 葛蘭素史密斯克萊有限責任公司
Publication of TW201313705A publication Critical patent/TW201313705A/zh
Application granted granted Critical
Publication of TWI538912B publication Critical patent/TWI538912B/zh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10Laxatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12Antidiarrhoeals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/10Drugs for disorders of the urinary system of the bladder
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10Antioedematous agents; Diuretics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D419/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms
    • C07D419/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Otolaryngology (AREA)
  • Communicable Diseases (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
TW101121449A 2011-06-17 2012-06-15 Trpv4拮抗劑 TWI538912B (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161498110P 2011-06-17 2011-06-17

Publications (2)

Publication Number Publication Date
TW201313705A TW201313705A (zh) 2013-04-01
TWI538912B true TWI538912B (zh) 2016-06-21

Family

ID=47558389

Family Applications (1)

Application Number Title Priority Date Filing Date
TW101121449A TWI538912B (zh) 2011-06-17 2012-06-15 Trpv4拮抗劑

Country Status (38)

Country Link
US (1) US9187464B2 (https=)
EP (2) EP3121177B1 (https=)
JP (1) JP5969017B2 (https=)
KR (1) KR101870003B1 (https=)
CN (1) CN103732583B (https=)
AR (1) AR086958A1 (https=)
AU (1) AU2012284540B2 (https=)
BR (1) BR112013032391B1 (https=)
CA (1) CA2839743C (https=)
CL (1) CL2013003602A1 (https=)
CO (1) CO6821953A2 (https=)
CR (1) CR20130671A (https=)
CY (1) CY1117792T1 (https=)
DK (1) DK2721016T3 (https=)
DO (1) DOP2013000307A (https=)
EA (1) EA023616B1 (https=)
ES (2) ES2688733T3 (https=)
HR (1) HRP20160539T1 (https=)
HU (1) HUE029594T2 (https=)
IL (1) IL229872A (https=)
JO (1) JO3154B1 (https=)
MA (1) MA35184B1 (https=)
ME (1) ME02416B (https=)
MX (1) MX337440B (https=)
MY (1) MY173521A (https=)
PE (1) PE20141943A1 (https=)
PH (1) PH12013502463A1 (https=)
PL (1) PL2721016T3 (https=)
PT (1) PT2721016E (https=)
RS (1) RS54858B1 (https=)
SG (1) SG195106A1 (https=)
SI (1) SI2721016T1 (https=)
SM (1) SMT201600150B (https=)
TW (1) TWI538912B (https=)
UA (1) UA113963C2 (https=)
UY (1) UY34138A (https=)
WO (1) WO2013012500A1 (https=)
ZA (1) ZA201308816B (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2720546B1 (en) 2011-06-17 2016-04-06 Glaxosmithkline Intellectual Property (No. 2) Limited Spiro-cyclic trpv4 antagonists
US8927585B2 (en) * 2011-06-17 2015-01-06 Glaxosmithkline Intellectual Property (No.2) Limited TRPV4 antagonists
WO2013146754A1 (ja) 2012-03-27 2013-10-03 塩野義製薬株式会社 Trpv4阻害活性を有する芳香族複素5員環誘導体
WO2015046193A1 (ja) 2013-09-25 2015-04-02 塩野義製薬株式会社 Trpv4阻害活性を有する芳香族複素環式アミン誘導体
CN109153672B (zh) * 2016-05-19 2021-12-07 葛兰素史密斯克莱知识产权(第2 号)有限公司 Trpv4拮抗剂
US10968209B2 (en) 2016-05-19 2021-04-06 Glaxosmithkline Intellectual Property (No.2) Limited TRPV4 antagonist
TN2019000087A1 (en) 2016-10-03 2020-07-15 Janssen Pharmaceutica Nv Novel monocyclic and bicyclic ring system substituted carbanucleoside analogues for use as prmt5 inhibitors
WO2018185701A1 (en) 2017-04-06 2018-10-11 Glaxosmithkline Intellectual Property (No.2) Limited Trpv4 antagonists as antitussive agents
CA3081424A1 (en) * 2017-11-01 2019-05-09 Bristol-Myers Squibb Company Spirocyclic compounds as farnesoid x receptor modulators
WO2021170811A1 (en) 2020-02-27 2021-09-02 Glaxosmithkline Intellectual Property (No.2) Limited Method of treating eye disease using trpv4 antagonists
JP7692219B2 (ja) 2020-04-30 2025-06-13 ラクオリア創薬株式会社 Trpv4拮抗薬としてのピリミジン-4(3h)-オン誘導体
CN111704613B (zh) * 2020-06-23 2021-07-06 中国人民解放军军事科学院军事医学研究院 咪唑类衍生物及其作为trpv4抑制剂的用途
JPWO2022014707A1 (https=) * 2020-07-16 2022-01-20
WO2024011214A1 (en) 2022-07-08 2024-01-11 Actio Biosciences, Inc. Therapeutic compounds and methods
CN120641413A (zh) * 2023-04-18 2025-09-12 河北乌图药业有限公司 化合物及其在慢性乙型肝炎、肝纤维化、肝癌的治疗中的应用
WO2024217446A1 (zh) * 2023-04-18 2024-10-24 河北乌图药业有限公司 化合物及其在慢性乙型肝炎、肝纤维化、肝癌的治疗中的应用
WO2024217452A1 (zh) * 2023-04-18 2024-10-24 河北乌图药业有限公司 化合物及其在慢性乙型肝炎、肝纤维化、肝癌的治疗中的应用
WO2024217439A1 (zh) * 2023-04-18 2024-10-24 河北乌图药业有限公司 化合物及其在慢性乙型肝炎、肝纤维化、肝癌的治疗中的应用
CN120435476A (zh) * 2023-04-18 2025-08-05 河北乌图药业有限公司 化合物及其在慢性乙型肝炎、肝纤维化、肝癌的治疗中的应用
WO2025014818A1 (en) * 2023-07-07 2025-01-16 Actio Biosciences, Inc. Solid forms of gsk2798745, a trpv4 antagonist
CN117945917A (zh) * 2023-12-26 2024-04-30 衢州康鹏化学有限公司 一种3-氟-4-硝基苯甲酸的制备方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE482945T1 (de) * 1998-05-26 2010-10-15 Chugai Pharmaceutical Co Ltd Heterozyklische indolderivate und mono- oder diazaindol-derivate
CA2531619A1 (en) * 2003-07-16 2005-01-27 Neurogen Corporation Biaryl piperazinyl-pyridine analogues
WO2007059608A1 (en) * 2005-11-23 2007-05-31 Painceptor Pharma Corporation Compositions and methods for modulating gated ion channels
WO2007067756A2 (en) 2005-12-08 2007-06-14 Amphora Discovery Corporation Certain chemical entities, compositions, and methods for modulating trpv1
AU2006327181A1 (en) * 2005-12-22 2007-06-28 Hydra Biosciences, Inc. TRPA1 inhibitors for treating pain
TW200819457A (en) * 2006-08-30 2008-05-01 Actelion Pharmaceuticals Ltd Spiro antibiotic derivatives
PE20081735A1 (es) * 2007-02-01 2009-01-18 Glaxo Group Ltd Derivados de 1-oxa-3[4,5]decan-2-ona en el tratamiento de trastornos alimenticios
GB0707934D0 (en) * 2007-04-24 2007-05-30 Glaxo Group Ltd Chemical compounds
EP2185538A2 (en) * 2007-08-09 2010-05-19 Abbott Laboratories Tetrahydropyridine carboxamide derivatives as trpvl antagonists
TW200944520A (en) * 2008-01-29 2009-11-01 Glaxo Group Ltd Spiro compounds as NPY Y5 receptor antagonists
JP5607046B2 (ja) * 2008-07-25 2014-10-15 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー Trpv4拮抗薬
JP2012006837A (ja) * 2008-09-30 2012-01-12 Mochida Pharmaceut Co Ltd 2−インドールアクリルアミド類縁体
WO2012024183A1 (en) * 2010-08-18 2012-02-23 Merck Sharp & Dohme Corp. Spiroxazolidinone compounds
US8927585B2 (en) * 2011-06-17 2015-01-06 Glaxosmithkline Intellectual Property (No.2) Limited TRPV4 antagonists
EP2720546B1 (en) * 2011-06-17 2016-04-06 Glaxosmithkline Intellectual Property (No. 2) Limited Spiro-cyclic trpv4 antagonists

Also Published As

Publication number Publication date
JO3154B1 (ar) 2017-09-20
PE20141943A1 (es) 2014-12-28
ZA201308816B (en) 2015-02-25
EP3121177A1 (en) 2017-01-25
CR20130671A (es) 2014-02-04
CN103732583B (zh) 2015-12-23
EP3121177B1 (en) 2018-08-01
HUE029594T2 (en) 2017-03-28
CA2839743A1 (en) 2013-01-24
JP5969017B2 (ja) 2016-08-10
HK1195068A1 (zh) 2014-10-31
NZ618221A (en) 2015-02-27
PT2721016E (pt) 2016-06-06
EA023616B1 (ru) 2016-06-30
MY173521A (en) 2020-01-30
HRP20160539T1 (hr) 2016-06-17
EP2721016A1 (en) 2014-04-23
ES2688733T3 (es) 2018-11-06
JP2014518214A (ja) 2014-07-28
CY1117792T1 (el) 2017-05-17
CN103732583A (zh) 2014-04-16
AU2012284540A1 (en) 2013-04-04
SG195106A1 (en) 2013-12-30
MA35184B1 (fr) 2014-06-02
SI2721016T1 (sl) 2016-06-30
DOP2013000307A (es) 2014-06-01
CO6821953A2 (es) 2013-12-31
ES2569193T3 (es) 2016-05-09
UY34138A (es) 2013-01-03
MX337440B (es) 2016-03-03
IL229872A (en) 2017-03-30
AU2012284540B2 (en) 2014-08-28
BR112013032391A2 (pt) 2016-08-16
RS54858B1 (sr) 2016-10-31
DK2721016T3 (en) 2016-06-06
KR20140041733A (ko) 2014-04-04
CA2839743C (en) 2017-03-28
KR101870003B1 (ko) 2018-06-22
ME02416B (me) 2016-09-20
BR112013032391B1 (pt) 2020-11-24
EP2721016A4 (en) 2014-10-08
CL2013003602A1 (es) 2014-07-04
EP2721016B1 (en) 2016-04-06
PL2721016T3 (pl) 2017-01-31
SMT201600150B (it) 2016-07-01
TW201313705A (zh) 2013-04-01
MX2013014898A (es) 2014-03-21
US20140121206A1 (en) 2014-05-01
EA201490037A1 (ru) 2015-12-30
AR086958A1 (es) 2014-02-05
UA113963C2 (xx) 2017-04-10
WO2013012500A1 (en) 2013-01-24
PH12013502463A1 (en) 2014-01-20
US9187464B2 (en) 2015-11-17

Similar Documents

Publication Publication Date Title
TWI538912B (zh) Trpv4拮抗劑
KR101962495B1 (ko) C-kit 키나제 억제제로서의 화합물 및 조성물
JP6976953B2 (ja) Rock阻害剤としてのスピロヘプタンサリチルアミドおよび関連性化合物
TWI531572B (zh) 作為jak1抑制劑之哌啶-4-基三亞甲亞胺衍生物
KR101959590B1 (ko) c-KIT 키나제 억제제로서의 화합물 및 조성물
TWI789381B (zh) 雜環化合物
CA3161278A1 (en) Sos1 inhibitors
AU2024227155A1 (en) Carboxy-benzimidazole GLP-1R modulating compounds.
TW201910328A (zh) 雜環化合物
EA027138B1 (ru) Фталазиноны и изохинолиноны в качестве ингибиторов rock
MX2013005603A (es) Derivados de pirrolopiridina sustituidos con ciclobutilo como inhibidores de janus cinasas (jak).
JP2017510653A (ja) PARP阻害剤としての4H‐ピラゾロ[1,5‐α]ベンゾイミダゾール化合物のアナログ
AU2021289169B2 (en) Spiro compounds as melanocortin 4 receptor antagonists and uses thereof
TW202334167A (zh) 作為erbb2抑制劑之稠合四環喹唑啉衍生物
TW202421130A (zh) 作為pi3k抑制劑的異喹啉酮
TW202140499A (zh) 巨環rip2-激酶抑制劑
TW202602873A (zh) 新穎降解劑化合物及其用途
EA051124B1 (ru) Спиросоединения в качестве антагонистов рецептора меланокортина 4 и их применения
HK1195068B (en) Trpv4 antagonists
NZ618221B2 (en) Trpv4 antagonists